Article citationsMore>>

Nagendran, J., Archer, S.L., Soliman, D., et al. (2007) Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation, 116, 238-248. doi:10.1161/CIRCULATIONAHA.106.655266

has been cited by the following article:

• TITLE: Combined phosphodiesterase inhibitors in end-stage heart failure: A case presentation

  AUTHORS: Javier Reyna, Julio G. Peguero, Esteban Escolar, Orlando Santana, Gervasio A. Lamas

  KEYWORDS: Heart Failure; Phosphodiesterase Inhibitors

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.3 No.3, June 4, 2013

  ABSTRACT: Heart failure (HF) is the leading cause of morbidity and mortality and is evolving to epidemic proportions. Despite pharmacologic advances and device interventions, HF remains a progressive disease. The phosphodiesterase inhibitors-3 (PDE3I), and more recently, the phosphodiesterase inhibitors-5 (PDE5I) have been used as part of the treatment in certain patients, however, such combination has not been studied or reported before.